MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 17, 2021

Primary Completion Date

April 14, 2027

Study Completion Date

January 20, 2029

Conditions
Rectal Adenocarcinoma
Interventions
DRUG

Capecitabine

825 mg/m\^2 twice daily during radiation therapy. (Fluorouracil (5-FU) may be used at the discretion of the treating medical oncologists.) This chemotherapy will be given during the initial radiation dose (50 Gy over 25 frac) and continue for Cohorts A, B, and C.

DEVICE

Initial Dose of Radiation before Dose Escalation

50 Gy over 25 frac.

DEVICE

Cohort A: Dose Escalation Radiation

Cohort A will receive 14 Gy boost for a total of 64 Gy over 32 total fractions.

DEVICE

Cohort B: Dose Escalation Radiation

Cohort B will receive 18 Gy boost for a total of 68 Gy over 34 total fractions.

DEVICE

Cohort C: Dose Escalation Radiation

Cohort C will receive 22 Gy boost for a total of 72 Gy over 36 total fractions.

DRUG

FOLFOX

After the completion of radiation, subjects will receive up to eight cycles of systemic chemotherapy. (FOLFIRINOX may be used at the discretion of the treating medical oncologists.)

Trial Locations (1)

53226

RECRUITING

Froedtert & the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT04808323 - MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer | Biotech Hunter | Biotech Hunter